evenfolio

Consumer Services · NSE: JSLL

Jeena Sikho Lifecare

Q2 FY27 earnings highlights, from the results presentation

Price as of 16 Nov 2026
310.45−9.25%

Q2 FY27 · From the investor presentation

Read the filing on NSEFiling

5,000​bedsTotal bed capacity · next two to five yearsSlides · p. 8
10,000​bedsTotal bed capacity · 5–10 YEARSSlides · p. 35
172​facilitiesNumber of hospitals and clinics · 5–10 YEARSSlides · p. 35
460​bedsBeds in pipelineSlides · p. 8
M.Cap
₹3,859Cr
P/E
18.0×
1Y return
−56.24%
From 52W high
−61.6%

Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.

Share price

Results Q2 FY27, as filed · consolidated · ₹ Cr

Q2 FY27Q2 FY26YoYQ1 FY27QoQ
Revenue235190+23.9%224+4.8%
EBITDA7292-21.8%92-21.8%
EBITDA margin30.6%48.5%-1785 bps41.0%-1041 bps
PBTProfit before tax5079-37.1%88-43.4%
Net profit3759-37.6%66-44.4%
EPS (₹)2.944.72-37.7%5.29-44.4%

From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures.

Guidance

New stores · long term172 facilitiesHospitals and clinics planned to go from 122 to 142 in 2–5 years and 172 in 5–10 years
Capex3-4 Rs lakhCapex per bed ₹3–4 lakh, varying by location and scale
Capacity · long term5,000 bedsPriority to scale towards 5,000 beds over the next two to five years

More figures from the presentation

Company · Capacity
160​bedsPlanned beds
“• Lucknow – 160 beds”
Slidesp. 51
Company · Capacity
40​bedsPlanned beds
“• Bareilly – 40 beds”
Slidesp. 51
Company · Capacity
200​bedsPlanned beds
“• Ahmedabad – 200 beds”
Slidesp. 51
Company · Capacity
60​bedsPlanned beds
“• Kalyani, West Bengal – 60 beds”
Slidesp. 51
premium wellness · Capacity
108​roomsResort rooms
“• 108 rooms, 22 villas and a helipad”
Slidesp. 34
Company · Capex
₹250–350​lakhCapex per 100-bed facility
“Total CAPEX ₹250 - 350 lakhs”
Slidesp. 30

In short

  1. 01H1 EBITDA was ₹164 crore at a 36% margin and PAT ₹102 crore; Q2 EBITDA margin was 31%.
  2. 02Higher advertising (₹13.4 crore), staff (₹4.1 crore) and ECL provision (₹2.5 crore) costs were cited.
  3. 03Company aims for about 5,000 beds in 2-5 years and 10,000 in 5-10 years, from 3,031 now.
  4. 04Network is 2,424 operational beds with 460 in pipeline, including four upcoming facilities.
  5. 05Growth is to be funded from internal accruals with a debt-free balance sheet.
  6. 06Company has signed its first wellness resort in Manali, entering premium wellness.

Capacity

Bed occupancy 57.0% in H1 FY27, same as H1 FY26

Slides · p. 13
“No. of Operational beds Occupancy 57.0% 57.0%”

Segments

Ayurveda Healthcare Products: H1 products revenue ₹262 crore (57%) and services ₹197 crore (43%)

Slides · p. 8
“The business is now well balanced: Ayurveda Healthcare Products contributed ₹262 crore (57%) and Healthcare Services ₹197 crore (43%) in H1FY27, with gross margins”

Demand

H1 IPD volumes up 23% to 22,480; OPD volumes up 17% to 3.1 lakh

Slides · p. 8
“IPD volumes grew 23% YoY to 22,480, OPD volumes grew 17% to 3.1 lakh,”

Health camps convert about 30% of attendees to IPD treatment on average

Slides · p. 52
“Average ~30% conversion of camp attendees for IPD”

Most key Indian states are below WHO norm of 3.0 beds per 1,000 people

Slides · p. 48
“Most key Indian states fall significantly short of the WHO recommendation of 3.0 beds per 1,000 population, with major deficit in markets like Odisha, Uttar Pradesh and Haryana offering long-term structural expansion runway.”

Group and individual share of insured lives rose from 35% in FY18 to 58% in FY25

Slides · p. 48
“The combined share of Group + Individual policies in total lives covered surged from 35% in FY18 to 58%”

H1 FY27 day care volumes up 27%; virtual OPD consultations up 39% to 1.36 lakh

Slides · p. 8
“day care volumes grew 27%, and virtual OPD consultations grew 39% to 1.36”

Margins and costs

Growth was volume-led in both verticals; gross margin held at 88%

Slides · p. 8
“volume-led across both verticals, and gross margin held firm at 88%, underlining the pricing strength of our integrated model.”

H1 EBITDA ₹164 crore at 36% margin, PAT ₹102 crore; Q2 EBITDA margin 31%

Slides · p. 8
“With depreciation also rising on the larger network, EBITDA stood at ₹164 crore with a margin of 36%, and PAT at ₹102 crore. Q2FY27 EBITDA margin was 31%.”

Advertisement and promotion expenses up Rs 13.4 crore for brand building aimed at Gen Z

Slides · p. 39
“Operating expense include Advertisement and promotion expenses increased by Rs. 13.4 crore driven by strategic brand building initiatives focused on expanding the company reach among younger consumer specifically Gen Z, including”

Employee expenses up Rs 4.1 crore from hiring ahead of expansion and salary revisions

Slides · p. 39
“Operating expense also includes Employee benefit expenses increased by Rs 4.1 crore due to additional manpower, hiring new talent in markets ahead of planned expansion and performance-linked salary revisions.”

Management expects operating leverage to return after brand and capability investments

Slides · p. 8
“These are investments in brand and capability, and we expect operating leverage to”

Debt and working capital

Debt-free balance sheet; growth to be funded from internal accruals

Slides · p. 8
“With a debt-free balance sheet, this growth remains funded from internal accruals.”

Free cash flow of ₹51 crore in FY26

Slides · p. 22
“₹51 Cr free cash flow in FY26 after”

Acquisitions and new business

premium wellness: First wellness resort signed in Manali, Himachal Pradesh

Slides · p. 34
“First wellness resort signed in Manali, Himachal Pradesh”

Ayurveda Healthcare Products: Upcoming product launches: Dr. DS range, protein and joint-care

Slides · p. 35
“• Dr. DS range, protein & joint-care launches”

Ayurveda Healthcare Products: Plans for own e-commerce platform and refill subscriptions

Slides · p. 35
“• Own e-commerce platform & refill subscriptions”

Ayurveda Healthcare Products: Pharmacy and retail roll-out in pipeline

Slides · p. 35
“• Pharmacy & retail roll-out in pipeline”

Dividends and buybacks

Company cites consistent and growing dividend payout

Slides · p. 23
“• Consistent & growing dividend payout in”

Management

Forvis Mazars appointed as new internal auditor

Slides · p. 23
“• Forvis Mazars Appointed as the new Internal”

One-offs

Q2 FY27 other income was negative ₹231 lakh versus ₹1,402 lakh in Q1

Slides · p. 39
“OTHER INCOME (231) 1,402 (116%) 144 (260%)”

Risks

ECL provision up Rs 2.5 crore based on collection experience with government customers

Slides · p. 39
“Operating expense also includes ECL provision increased by Rs. 2.5 crore, reflecting a prudent provisioning approach based on recent collection experience and settlement patterns from government customers.”

Other

Revenue from operations ₹460 crore in H1 FY27; Q2 FY27 ₹235 crore, up 24% YoY

Slides · p. 8
“YoY to ₹460 crore in H1FY27 and 24% YoY to ₹235 crore in Q2FY27.”

Q2 FY27 EBITDA ₹7,202 lakh, down 22% YoY and 22% QoQ

Slides · p. 39
“EBITDA 7,202 9,212 (22%) 9,206 (22%)”

Q2 FY27 PAT ₹3,634 lakh, down 45% QoQ and 38% YoY

Slides · p. 39
“PROFIT AFTER TAXES 3,634 6,569 (45%) 5,879 (38%)”

Priorities include entering premium wellness through first resort in Manali

Slides · p. 8
“enter premium wellness through our first resort in Manali.”

52 NABH-accredited units, 12 more in process

Slides · p. 8
“With 52 NABH-accredited units and 12 in process, quality remains central to”

Sources

Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

Search

Search funds, ETFs, stocks, pages and tools